Delivering on the promise of personalized healthcare

被引：10

作者：

March, Ruth ^{[1
]}

机构：

[1] AstraZeneca, Macclesfield SK10 4TG, Cheshire, England

来源：

PERSONALIZED MEDICINE | 2010年 / 7卷 / 03期

关键词：

biomarker; clinical development; diagnostics; partnership; personalized healthcare; regulatory assessment; CELL LUNG-CANCER; PREVIOUSLY TREATED PATIENTS; CLINICAL-TRIAL DESIGNS; TYROSINE KINASE; BREAST-CANCER; PHARMACOGENETICS; GEFITINIB; VALIDATION; STRATEGIES; INHIBITOR;

D O I：

10.2217/PME.10.17

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Personalized healthcare (PHC) aims to deliver the right medicine, to the right patient, at the right dose and time, and has the potential to benefit everyone in the healthcare system. Delivering the promise of PHC depends on overcoming key challenges (e.g., identifying biomarkers or disease segmentation tools, facilitating partnerships, clinical development, regulatory engagement and market access) in an integrated fashion. Despite this, progress in PHC has been accelerating over the last few years and is now at a turning point. Flexibility from all those involved in PHC, including the pharmaceutical and diagnostic industries, health authorities and payers, will be required to ensure that the field comes to maturity and delivers its potential to improve patients' lives.

引用

页码：327 / 337

页数：11

共 51 条

[1] Is personalized medicine finally arriving? [J].

Allison, Malorye .

NATURE BIOTECHNOLOGY, 2008, 26 (05) :509-517

[2] Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective [J].

Amur, Shashi ;

Frueh, Felix W. ;

Lesko, Lawrence J. ;

Huang, Shiew-Mei .

BIOMARKERS IN MEDICINE, 2008, 2 (03) :305-311

[3] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[4]

BASERGA A, 1973, BIOMEDICINE, V18, P89

[5] Recommendations from the EGAPP Working Group: can tumor gene expression in patients with breast cancer? [J].

Berg, Alfred O. ;

Grp, E. G. A. P. P. Working ;

Armstrong, Katrina ;

Botkin, Jeffrey ;

Calonge, Ned ;

Haddow, James ;

Hayes, Maxine ;

Kaye, Celia ;

Phillips, Kathryn A. ;

Piper, Margaret ;

Richards, Carolyn Sue ;

Scott, Joan A. ;

Strickland, Ora L. ;

Teutsch, Steven .

GENETICS IN MEDICINE, 2009, 11 (01) :66-73

[6] Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors [J].

Bonomi, Philip D. ;

Buckingham, Lela ;

Coon, John .

CLINICAL CANCER RESEARCH, 2007, 13 (15) :4606S-4612S

[7] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[8] Towards validation of statistically reliable biomarkers [J].

Buyse, Marc .

EJC SUPPLEMENTS, 2007, 5 (05) :89-95

[9] OUTLOOK The microeconomics of personalized medicine: today's challenge and tomorrow's promise [J].

Davis, Jerel C. ;

Furstenthal, Laura ;

Desai, Amar A. ;

Norris, Troy ;

Sutaria, Saumya ;

Fleming, Edd ;

Ma, Philip .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (04) :279-286

[10]

*DEL CTR HLTH SOL, 2009, ROI TARG THER STRAT

← 1 2 3 4 5 6 →